Literature DB >> 16226710

Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.

Robert Roskoski1.   

Abstract

Signaling by stem cell factor and Kit, its receptor, play important roles in gametogenesis, hematopoiesis, mast cell development and function, and melanogenesis. Moreover, human and mouse embryonic stem cells express Kit transcripts. Stem cell factor exists as both a soluble and a membrane-bound glycoprotein while Kit is a glycoprotein receptor protein-tyrosine kinase. The complete absence of stem cell factor or Kit is lethal. Gain-of-function mutations of Kit are associated with several human neoplasms including acute myelogenous leukemia, gastrointestinal stromal tumors, mastocytomas, and nasal T-cell lymphomas. Binding of stem cell factor to Kit results in receptor dimerization and activation of protein kinase activity. The activated receptor becomes autophosphorylated at tyrosine residues that serve as docking sites for signal transduction molecules containing SH2 domains. Kit activates Akt, Src family kinases, phosphatidylinositol 3-kinase, phospholipase Cgamma, and Ras/mitogen-activated protein kinases. Kit exists in active and inactive conformations as determined by X-ray crystallography. Kit consists of an extracellular domain, a transmembrane segment, a juxtamembrane domain, and a protein kinase domain that contains an insert of about 80 amino acid residues. The juxtamembrane domain inhibits enzyme activity in cis by maintaining the control alphaC-helix and the activation loop in their inactive conformations. The juxtamembrane domain also inhibits receptor dimerization. STI-571, a clinically effective targeted protein-tyrosine kinase inhibitor, binds to an inactive conformation of Kit. The majority of human gastrointestinal stromal tumors have Kit gain-of-function mutations in the juxtamembrane domain, and most people with these tumors respond to STI-571. STI-571 binds to Kit and Bcr-Abl (the oncoprotein of chronic myelogenous leukemia) at their ATP-binding sites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226710     DOI: 10.1016/j.bbrc.2005.09.150

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  95 in total

1.  KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.

Authors:  Youl-Nam Lee; Stephanie Brandal; Pierre Noel; Erik Wentzel; Joshua T Mendell; Michael A McDevitt; Reuben Kapur; Melody Carter; Dean D Metcalfe; Clifford M Takemoto
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

2.  Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Authors:  Heidi J Nick; Hyung-Gyoon Kim; Chia-Wei Chang; Kevin W Harris; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

3.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

4.  Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.

Authors:  Yan-Jun Mi; Yong-Ju Liang; Hong-Bing Huang; Hong-Yun Zhao; Chung-Pu Wu; Fang Wang; Li-Yang Tao; Chuan-Zhao Zhang; Chun-Ling Dai; Amit K Tiwari; Xiao-Xu Ma; Kenneth Kin Wah To; Suresh V Ambudkar; Zhe-Sheng Chen; Li-Wu Fu
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

5.  Generation and characterization of novel canine malignant mast cell line CL1.

Authors:  Tzu-Yin Lin; Rachael Thomas; Pei-Chien Tsai; Matthew Breen; Cheryl A London
Journal:  Vet Immunol Immunopathol       Date:  2008-10-11       Impact factor: 2.046

Review 6.  Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells.

Authors:  S Sell
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 5.739

7.  Glycogen synthase kinase 3beta activation is a prerequisite signal for cytokine production and chemotaxis in human mast cells.

Authors:  Madeleine Rådinger; Hye Sun Kuehn; Mi-Sun Kim; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

Review 8.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  Characterization of c-kit (CD117) expression in human normal pituitary cells and pituitary adenomas.

Authors:  Stefano La Rosa; Silvia Uccella; Linda Dainese; Silvia Marchet; Claudia Placidi; Davide Vigetti; Carlo Capella
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

10.  The c-kit signaling pathway is involved in the development of persistent pain.

Authors:  Yan-Gang Sun; Neilia G Gracias; Julie Kosto Drobish; Michael R Vasko; Robert W Gereau; Zhou-Feng Chen
Journal:  Pain       Date:  2009-05-13       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.